Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
23 mars 2021 16h05 HE
|
Kronos Bio, Inc.
Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia First patient dosed in Phase 1/2 trial of KB-0742, an oral CDK9 inhibitor...
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
10 mars 2021 16h35 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
04 mars 2021 07h00 HE
|
Kronos Bio, Inc.
Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval First time MRD could serve...
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
25 févr. 2021 08h00 HE
|
Kronos Bio, Inc.
KB-0742 generated using the company’s proprietary small molecule microarray (SMM) screening platform Initial safety, pharmacokinetic and pharmacodynamic data expected in fourth quarter of 2021 SAN...
Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference
22 févr. 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
26 janv. 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical Development
08 déc. 2020 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
07 déc. 2020 08h00 HE
|
Kronos Bio, Inc.
MYC amplification found in approximately 30% of solid tumors Phase 1/2 clinical trial to begin in the first quarter of 2021 KB-0742 generated using the company’s proprietary small molecule...
Kronos Bio Announces Participation in Upcoming Investor Conferences
23 nov. 2020 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
18 nov. 2020 08h00 HE
|
Kronos Bio, Inc.
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia ...